




FIG.1

2/9




FIG. 2







FIG. 3









FIG. 4





FIG. 5



7/9

A	day 34		day 208		day 257	
	IL-5	IFN- γ	IL-5	IFN- γ	IL-5	IFN- γ
PBS	1.00	2.00	1.00	1.00	5.00	2.00
gB and pentamer	22.00	5.00	2.00	2.00	125.00	6.00
+MF59	60.00	10.00	21.00	1.00	268.00	3.00
+PAA	5.00	15.00	9.00	1.00	38.00	11.00
+AF04	13.00	9.00	7.00	1.00	15.00	7.00
+GLA-SQEM	13.00	12.00	2.00	1.00	3.00	63.00

B	day 34		day 208		day 257	
	IL-5	IFN- γ	IL-5	IFN- γ	IL-5	IFN- γ
PBS	1.00	2.00	1.00	2.00	6.00	4.00
gB and pentamer	251.00	7.00	140.00	1.00	3077.00	66.00
+MF59	444.00	26.00	277.00	1.00	2284.00	52.00
+PAA	82.00	462.00	108.00	16.00	330.00	848.00
+AF04	170.00	722.00	38.00	117.00	546.00	645.00
+GLA-SQEM	40.00	299.00	23.00	45.00	38.00	1405.00

FIG. 8

A	day 34		day 208		day 257	
	%IgG1	%IgG2c	%IgG1	%IgG2c	%IgG1	%IgG2c
gB+pentamer	0.46	0.00	0.00	0.00	0.71	0.04
+MF59	12.37	0.63	0.58	0.09	3.95	0.42
+PAA	6.63	14.76	0.40	2.59	6.88	9.87
+AF04	20.12	12.24	0.57	0.30	7.42	2.87
+GLA-SQEM	4.03	3.26	0.35	1.11	2.44	4.62



B	day 34		day 208		day 257	
	%IgG1	%IgG2c	%IgG1	%IgG2c	%IgG1	%IgG2c
gB+pentamer	0.08	0.08	0.00	0.00	0.41	0.04
+MF59	7.02	0.95	0.34	0.11	3.54	0.32
+PAA	3.80	5.00	0.24	0.81	4.58	5.25
+AF04	12.03	15.00	0.64	0.55	9.00	3.81
+GLA-SQEM	7.15	4.00	0.08	1.67	3.11	5.59

FIG. 9

A	day 34		day 208		day 257	
	%IgG1	%IgG2c	%IgG1	%IgG2c	%IgG1	%IgG2c
gB+pentamer	0.03	0.00	0.10	0.05	0.43	0.03
+MF59	4.29	0.34	0.99	0.09	1.33	0.12
+PAA	1.64	3.66	0.83	1.24	2.43	3.38
+AF04	2.62	1.53	0.78	0.50	1.79	0.65
+GLA-SQEM	1.54	3.81	0.58	0.57	1.24	2.17


B	day 34		day 208		day 257	
	%IgG1	%IgG2c	%IgG1	%IgG2c	%IgG1	%IgG2c
gB+pentamer	0.04	0.00	0.33	0.03	0.55	0.06
+MF59	4.68	0.75	1.88	0.08	1.91	0.18
+PAA	1.83	2.04	3.24	0.71	3.69	3.45
+AF04	2.57	1.69	1.62	0.55	3.75	1.15
+GLA-SQEM	1.99	3.63	1.36	1.79	2.42	2.58

FIG. 10




Antigen Ratio in µg gB/Pentamer	D20 Neutralizing antibody titers (GMT, n=10) in presence of Complement	
	Epithelial cells	Fibroblasts
0/1.25	82	23
0/2.5	207	39
0/3.75	189	52
1.2/1.25	297	143
2/0	264	96
2/2.5	579	219
2/5	513	208
2.5/3.6	588	227
5/1.25	736	300
5/3.75	836	249

Antigen Ratio in µg gB/Pentamer	D35 Neutralizing antibody titers (GMT, n=10) in presence of Complement	
	Epithelial cells	Fibroblasts
0/1.25	9736	2263
0/2.5	12091	2613
0/3.75	26287	3981
1.2/1.25	10452	3176
2/0	8769	2887
2/2.5	17127	5435
2/5	23320	6307
2.5/3.6	20117	7519
5/1.25	14018	4363
5/3.75	17903	6747



D35 IFN- γ cellular response (ELISPOT)



In-vitro Stimulation with 15-mer peptide pools covering the sequence of each protein from the pentamer

